Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (41-50 of 721) with videos related to

Pageof 73
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 22, 2022
Tackling the Last Mile: A Major Component to Successfully Establish Radioligand TherapyKelsey L Pomykala, Marcus Würker, Ken Herrmann
Endocrine|June 19, 2015
Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomographyConstantin Lapa, Rudolf A Werner, Ken Herrmann
European Journal of Nuclear Medicine and Molecular Imaging|March 29, 2011
PET/CT for staging lung cancer: costly or cost-saving?Andreas K Buck, Ken Herrmann, Jonas Schreyögg
Nuklearmedizin. Nuclear Medicine|April 29, 2020
Impact of COVID-19 on Nuclear Medicine in Germany, Austria and Switzerland: An International Survey in April 2020Lutz S Freudenberg, Ulf Dittmer, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship: A Conversation with Ken Herrmann and Johannes CzerninArie S Belldegrun, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 2023
Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes CzerninDiane M Simeone, Ken Herrmann, Johannes Czernin
International Journal of Molecular Sciences|February 15, 2022
Chaperone Therapy in Fabry DiseaseFrank Weidemann, Ana Jovanovic, Ken Herrmann, et al.
PET Clinics|April 30, 2023
Fibroblast Activation Protein as a Diagnostic and Therapeutic Target: Where Do We Go from Here?Rodney J Hicks, Frederik L Giesel, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1Catello Somma, Richard Zimmermann, Germo Gericke, et al.
Deutsches Arzteblatt International|March 29, 2018
CUP Syndrome-Metastatic Malignancy with Unknown Primary TumorGregor Zaun, Martin Schuler, Ken Herrmann, et al.
Pageof 73

Showing results (41-50 of 721) with videos related to

Sort By:
Pageof 73
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 22, 2022
Tackling the Last Mile: A Major Component to Successfully Establish Radioligand TherapyKelsey L Pomykala, Marcus Würker, Ken Herrmann
Endocrine|June 19, 2015
Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomographyConstantin Lapa, Rudolf A Werner, Ken Herrmann
European Journal of Nuclear Medicine and Molecular Imaging|March 29, 2011
PET/CT for staging lung cancer: costly or cost-saving?Andreas K Buck, Ken Herrmann, Jonas Schreyögg
Nuklearmedizin. Nuclear Medicine|April 29, 2020
Impact of COVID-19 on Nuclear Medicine in Germany, Austria and Switzerland: An International Survey in April 2020Lutz S Freudenberg, Ulf Dittmer, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship: A Conversation with Ken Herrmann and Johannes CzerninArie S Belldegrun, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 2023
Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes CzerninDiane M Simeone, Ken Herrmann, Johannes Czernin
International Journal of Molecular Sciences|February 15, 2022
Chaperone Therapy in Fabry DiseaseFrank Weidemann, Ana Jovanovic, Ken Herrmann, et al.
PET Clinics|April 30, 2023
Fibroblast Activation Protein as a Diagnostic and Therapeutic Target: Where Do We Go from Here?Rodney J Hicks, Frederik L Giesel, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1Catello Somma, Richard Zimmermann, Germo Gericke, et al.
Deutsches Arzteblatt International|March 29, 2018
CUP Syndrome-Metastatic Malignancy with Unknown Primary TumorGregor Zaun, Martin Schuler, Ken Herrmann, et al.
Pageof 73